ReviewNeuroscience letters2011
Use of peripheral blood transcriptome biomarkers for epilepsy prediction.
Review in Neuroscience letters, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Transcriptome profiling reveals major structural genes, transcription factors and biosynthetic pathways in refractory epilepsy in tropical region of China.BMC neurology · 2025Article
- Assessing the potential relevance of CEACAM6 as a blood transcriptional biomarker.F1000Research · 2022Article
- BloodGen3Module: blood transcriptional module repertoire analysis and visualization using R.Bioinformatics (Oxford, England) · 2021Article
- The Human Blood Transcriptome in a Large Population Cohort and Its Relation to Aging and Health.Frontiers in big data · 2020Article
- Expression analysis of vitamin D receptor-associated lncRNAs in epileptic patients.Metabolic brain disease · 2019Article
- The ESC/E(Z) complex, an effector of response to ovarian steroids, manifests an intrinsic difference in cells from women with premenstrual dysphoric disorder.Molecular psychiatry · 2017Article
- Understanding epigenetic architecture of suicide neurobiology: A critical perspective.Neuroscience and biobehavioral reviews · 2017Review
- A Putative Blood-Based Biomarker for Autism Spectrum Disorder-Associated Ileocolitis.Scientific reports · 2016Article
- Profiles of multidrug resistance protein-1 in the peripheral blood mononuclear cells of patients with refractory epilepsy.PloS one · 2012Article
- New strategies for preventing epileptogenesis: perspective and overview.Neuroscience letters · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
There are currently no predictive methods to identify patients who suffered an initial brain injury and are at high risk of developing chronic epilepsy. Consequently, treatments aimed at epilepsy prevention that would target the underlying epileptogenic process are neither available nor being developed. After a brain injury or any other initial precipitating event (IPE) to the development of epilepsy, pathological changes may occur in forms of inflammation, damage in the blood brain barrier, neuron loss, gliosis, axon sprouting, etc., in multiple brain areas. Recent studies provide connections between various kinds of brain pathology and alterations in the peripheral blood transcriptome. In this review we discuss the possibility of using peripheral blood transcriptome biomarkers for the detection of epileptogenesis and consequently, subjects at high risk of developing epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.